ARScience Biotherapeutics

Executive Summary

ARScience Biotherapeutics is a clinical-stage biotechnology company focused on developing customized interleukin-based biologics for in vivo therapeutic use. Founded in 2021 and headquartered in Durham, North Carolina, the company aims to shape immunotherapy by creating tailored cytokine solutions that improve patient outcomes. With a platform designed to engineer interleukins with enhanced specificity and reduced toxicity, ARScience targets a range of immune-mediated diseases, including oncology and autoimmune indications. The company's lead program is currently in Phase 1 clinical development, reflecting its transition from preclinical to early human testing. As a private entity, ARScience has not disclosed its total funding or valuation, but its specialized approach to cytokine engineering positions it in a competitive and rapidly evolving biotech landscape.

Upcoming Catalysts (preview)

• H2 2026Phase 1 interim safety and pharmacodynamic data readout30% success
• 2026Potential strategic partnership for platform technology25% success
• 2026Series A or Series B financing round to fund clinical development40% success